Infliximab-related seizures: A first case study

Epileptic Disorders

Volumn 13, Issue 2, 2011, Pages 214-217

  Brigo, Francesco ^a   Bongiovanni, Luigi Giuseppe ^a   Cerini, Roberto ^b   Manganotti, Paolo ^a   Storti, Monica ^a   Fiaschi, Antonio ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

EEG; grey matter encephalopathy; infliximab; posterior reversible encephalopathy syndrome; seizures; TNF antagonists

Indexed keywords

GADOLINIUM; INFLIXIMAB; MESALAZINE; PREDNISONE;

AGED; AGGRESSIVENESS; AMNESIA; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN DISEASE; BRAIN INFARCTION; BRAIN ISCHEMIA; CASE REPORT; CONFUSION; CONSCIOUSNESS DISORDER; CONTRAST ENHANCEMENT; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISORIENTATION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EPILEPTIC DISCHARGE; HUMAN; HYPONATREMIA; MALE; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SEIZURE;

AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; SEIZURES;

EID: 80051598811     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2011.0439     Document Type: Review

References (10)

1. ACR Hotline. FDA Advisory Committee Reviews Safety of TNF Inhibitors. Atlanta (GA). American College of Rheumatology, 2001.
2. F. Dicuonzo A. Salvati M. Palma, et al. 2009 Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings J Child Neurol 24 1013 1018 19307676 10.1177/0883073809332705
3. A. Erbetta A. Salmaggi A. Sghirlanzoni, et al. 2008 Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments Neurol Sci 29 131 137 18612759 10.1007/s10072-008- 0924-3 (Pubitemid 352003647)
4. J. Hinchey C. Chaves B. Appignani, et al. 1996 A reversible posterior leukoencephalopathy syndrome N Engl J Med 334 494 500 8559202 10.1056/NEJM199602223340803 1:STN:280:DyaK287lslSisQ%3D%3D (Pubitemid 26067737)
5. D. Khanna M. McMahon D.E. Furst 2004 Safety of tumour necrosis factor-alpha antagonists Drug Saf 27 307 324 15061685 10.2165/00002018- 200427050-00003 1:CAS:528:DC%2BD2cXkt1Shurg%3D (Pubitemid 38530461)
6. A. Minagar J.C. DeToledo S. Falcone 2001 Cortical-subcortical lesions in "reversible posterior leukoencephalopathy syndrome". Encephalopathy or seizures? J Neurol 248 537 540 11499651 10.1007/s004150170170 1:STN:280:DC%2BD3MvltlahsQ%3D%3D (Pubitemid 32661515)
7. D. Renard R. Westhovens E. Vandenbussche R. Vandenberghe 2004 Reversible posterior leucoencephalopathy during oral treatment with methotrexate J Neurol 251 226 228 14991361 10.1007/s00415-004-0287-5 (Pubitemid 38221640)
8. M.H. Schiff G.R. Burmester J.D. Kent, et al. 2006 Safety analyses of adalimumab (HUMIRA) in global clinical trials and US post-marketing surveillance of patients with rheumatoid arthritis Ann Rheum Dis 65 889 894 16439435 10.1136/ard.2005.043166 1:CAS:528:DC%2BD28XntF2lsr8%3D
9. V.L. Stott M.A. Hurrell T.J. Anderson 2005 Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed Intern Med J 35 83 90 15705136 10.1111/j.1445-5994.2004.00750.x 1:STN:280:DC%2BD2M%2Fns1Kktg%3D%3D (Pubitemid 40343439)
10. V. Zamvar I.D. Sugarman R.F. Tawfik J. Macmullen-Price J.W. Puntis 2009 Posterior reversible encephalopathy syndrome following infliximab infusion J Pediatr Gastroenterol Nut 48 102 105 10.1097/MPG.0b013e31818aedb4